Clinical Report: Trial Data Indicates Cell Therapy May Reverse GA Damage
Overview
A phase 1/2a clinical trial of OpRegen RPE cell therapy demonstrated significant visual acuity improvements in patients with geographic atrophy (GA) over 36 months, with an average gain of +9 ETDRS letters specifically at this time point, suggesting potential for restoring vision in dry age-related macular degeneration (AMD) patients.
Background
Geographic atrophy (GA) is a severe manifestation of nonexudative age-related macular degeneration (AMD) and a leading cause of irreversible vision loss in older adults. Current treatments primarily slow GA progression without improving visual acuity, highlighting the need for innovative therapies. Cell therapies like OpRegen represent a novel approach that may offer functional benefits alongside structural improvements.
Data Highlights
| Time Point | BCVA Gain (ETDRS Letters) |
|---|---|
| Baseline | - |
| 12 months | +7.7 |
| 24 months | +5.5 |
| 36 months | +9 |
Key Findings
- OpRegen therapy resulted in an average gain of +9 ETDRS letters at 36 months.
- Significant visual acuity improvements were observed in eyes with extensive coverage of GA lesions.
- Patients with limited cell coverage showed lesser gains compared to those with extensive coverage, with specific average gains noted.
- The untreated fellow eyes demonstrated stability for the first two years but declined significantly by year three.
- Results indicate a potential dose-response relationship between cell coverage and visual acuity improvement.
Clinical Implications
The findings suggest that OpRegen cell therapy could be a transformative option for patients with GA, potentially improving visual outcomes where current therapies fall short. Clinicians should assess the extent of GA coverage and consider strategies to maximize visual acuity gains based on individual patient profiles.
Conclusion
OpRegen cell therapy shows promise in reversing GA damage and improving visual acuity, marking a significant advancement in the treatment landscape for AMD. Further studies are warranted to confirm these findings and optimize treatment protocols, including exploring different dosing strategies.
References
- Retinal Physician, 2025 -- Trial Data Indicates Cell Therapy May Reverse GA Damage
- Retinal Physician, 2026 -- The Therapeutic Pipeline for Geographic Atrophy
- Retinal Physician, 2020 -- CLINICAL TRIAL DOWNLOAD: Data on a Gene Therapy for Dry and Wet AMD
- Retinal Physician, 2026 -- Gene Therapy for GA Receives FDA Fast Track Designation
- Oregon Health & Science University -- Age-Related Macular Degeneration Preferred Practice Pattern®
- The ASCO Post — Gene Therapy Betters Chemotherapy Tolerance, Effectiveness in Small Glioblastoma Study
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- Trial Data Indicates Cell Therapy May Reverse GA Damage | Retinal Physician
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.